"Jurkat Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
| Descriptor ID |
D019169
|
| MeSH Number(s) |
A11.251.210.190.495 A11.251.860.180.495 A15.382.490.555.567.569.440
|
| Concept/Terms |
Jurkat Cells- Jurkat Cells
- Cell, Jurkat
- Cells, Jurkat
- Jurkat Cell
|
Below are MeSH descriptors whose meaning is more general than "Jurkat Cells".
Below are MeSH descriptors whose meaning is more specific than "Jurkat Cells".
This graph shows the total number of publications written about "Jurkat Cells" by people in this website by year, and whether "Jurkat Cells" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 11 | 11 |
| 1999 | 0 | 8 | 8 |
| 2000 | 0 | 12 | 12 |
| 2001 | 0 | 14 | 14 |
| 2002 | 0 | 13 | 13 |
| 2003 | 1 | 15 | 16 |
| 2004 | 0 | 15 | 15 |
| 2005 | 0 | 18 | 18 |
| 2006 | 0 | 13 | 13 |
| 2007 | 0 | 18 | 18 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 6 | 6 |
| 2014 | 0 | 7 | 7 |
| 2015 | 0 | 9 | 9 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 3 | 4 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Jurkat Cells" by people in Profiles.
-
Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens. Front Immunol. 2021; 12:765898.
-
Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat Cell Biol. 2021 06; 23(6):631-641.
-
The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models. J Virol. 2021 05 24; 95(12).
-
Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen. PLoS One. 2021; 16(4):e0244771.
-
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Rep. 2021 04 13; 35(2):108984.
-
Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. J Immunother Cancer. 2021 03; 9(3).
-
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021 02 05; 12(1):832.
-
Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jan; 476(1):417-423.
-
CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Sci Rep. 2020 03 24; 10(1):5350.
-
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Res. 2020 06 01; 80(11):2298-2310.